Is Ketamine Therapy Legal in Canada?

Yes. Ketamine therapy is legal in Canada when delivered by a qualified prescriber in a clinical setting that meets provincial medical regulator requirements. The legal framework has three layers: the federal Controlled Drugs and Substances Act (CDSA) classifies ketamine as a Schedule I controlled substance, meaning it can only be prescribed by authorized health professionals; Health Canada has approved racemic ketamine as an anaesthetic and has separately approved Spravato (intranasal esketamine) for treatment-resistant depression as of May 2020; and provincial medical regulators (CPSA Alberta, CPSO Ontario, CPSBC British Columbia, CPSS Saskatchewan, CMQ Quebec, CPSM Manitoba, and the Atlantic colleges) set facility-accreditation standards specific to the route of administration. Off-label psychiatric use of ketamine is legal and clinically standard — off-label prescribing is supported by the Canadian Medical Protective Association and provincial colleges and is a widely used practice across Canadian medicine. This article explains how the layers fit together and how ATMA CENA operates within them.

Key takeaways

• Ketamine is Schedule I under the federal Controlled Drugs and Substances Act — controlled, prescription-required, criminal penalties for unauthorized possession.
• Health Canada has approved ketamine as an anaesthetic. Psychiatric use is off-label, which is legal and standard medical practice — not "illegal" or "experimental."
• Spravato (intranasal esketamine) was Health Canada-approved in May 2020 for treatment-resistant MDD with concurrent oral SSRI/SNRI. Distribution is via the Janssen Journey program with mandatory in-clinic supervised administration.
• Provincial medical regulators set facility-accreditation rules specific to route — IV typically requires CPSA NSHF / CPSO OHPIP Level II / CPSBC NHMSFAP / CPSS NHTF facility accreditation in non-hospital settings; IM, SL, and intranasal routes generally have lighter requirements.
• Ketamine does NOT require Health Canada Special Access Program (SAP) authorization — it is already approved as an anaesthetic and Spravato is approved for TRD. SAP is the pathway for psilocybin and MDMA, which have no Canadian approved indication.
• Recreational possession is illegal under CDSA Schedule I and carries criminal penalties — the safety profile of supervised therapeutic ketamine is fundamentally different from recreational misuse.

The federal layer — CDSA Schedule I

Ketamine is controlled under Schedule I of the Controlled Drugs and Substances Act (CDSA). The practical implications:

• Prescription required. Ketamine can only be obtained through a prescription from a physician, nurse practitioner, or other authorized prescriber. There is no over-the-counter access.
• Recreational possession is illegal. Possession outside a prescription carries criminal penalties under the CDSA. This applies to all Schedule I substances.
• Manufacturing and distribution are tightly controlled. Pharmaceutical-grade ketamine is supplied through Health Canada-licensed manufacturers and dispensed through licensed pharmacies.
• Authorized therapeutic use is legal. Schedule I status does not prohibit medical use; it controls who may prescribe and dispense and under what conditions. Federal Health Canada framework: https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/ketamine.html.

The honest framing: a Schedule I classification creates strict regulatory controls but is not equivalent to "illegal." Many widely used medications are Schedule I — including morphine, fentanyl, and amphetamines — with the same regulatory framework: prescription-only, controlled distribution, and serious penalties for unauthorized possession.

The Health Canada approval layer

Racemic ketamine — approved as an anaesthetic

Pharmaceutical-grade racemic ketamine (the 50:50 mix of S- and R-enantiomers) has been Health Canada-approved as an anaesthetic for diagnostic and surgical procedures for decades. Brand names include Ketalar; multiple generic versions are available. The approved indication is anaesthesia.

Psychiatric use of racemic ketamine — for treatment-resistant depression, PTSD, anxiety, OCD, chronic pain — is off-label. Off-label means the indication is not on the manufacturer's product label, not that the use is illegal or experimental.

Spravato (esketamine) — approved for TRD

Health Canada approved Spravato (DIN 02499290) in May 2020 for treatment-resistant major depressive disorder in adults, in combination with oral SSRI or SNRI, after failure of at least two adequate antidepressant trials in the current depressive episode. See the Health Canada Drug Product Database entry.

Spravato distribution is controlled through the Janssen Journey program (the Canadian equivalent of the U.S. REMS framework). Requirements:

• Clinic, prescriber, and pharmacy must enroll in the program.
• Patients enroll at first dose.
• All doses are administered in-clinic under supervision — no take-home dispensing.
• Mandatory ≥2-hour post-dose observation.

For the modality-specific deep dive on Spravato in Canada, see Intranasal Ketamine and Spravato.

Off-label prescribing — legal and clinically standard

The single biggest source of patient confusion about ketamine legality is the off-label question. Here is the honest framing.

Off-label prescribing is legal in Canada. When a physician prescribes a Health Canada-approved medication for an indication that is not on the manufacturer's product label, that is off-label use. The Canadian Medical Protective Association (CMPA) explicitly recognizes off-label prescribing as a standard medical practice; provincial colleges (CPSA, CPSO, CPSBC, CMQ, etc.) support physician judgment on off-label indications when supported by clinical evidence and informed consent.

Off-label is normal in everyday Canadian medicine. Examples patients are likely to recognize:

• Gabapentin (Health Canada-approved for epilepsy and post-herpetic neuralgia) — widely prescribed off-label for neuropathic pain.
• Beta-blockers (approved for hypertension and cardiovascular conditions) — frequently prescribed off-label for performance anxiety or essential tremor.
• SSRIs (initially approved for major depressive disorder) — many specific indications now expanded by label, but historically routine off-label prescribing for OCD, PTSD, anxiety disorders.
• Bupropion (approved for depression and smoking cessation) — off-label for ADHD and sexual dysfunction.

Physician obligations for off-label use include informed consent (the patient must understand it is off-label and what that means), documented clinical rationale, evidence-based justification, and ongoing monitoring. ATMA CENA's intake call covers informed consent for off-label ketamine use as part of the standard process.

The practical takeaway: off-label ketamine use for psychiatric indications is legal Canadian medicine. Patients should not interpret "off-label" as "illegal" or "experimental."

The provincial layer — facility accreditation

Provincial medical regulators set facility-accreditation requirements for ketamine administration in non-hospital settings. The requirements are typically tied to the route of administration; intravenous (IV) administration is generally subject to the most stringent requirements.

The practical effect for patients: a clinic offering IV ketamine in a non-hospital setting must hold the appropriate provincial accreditation. Reputable clinics will state their accreditation status on request. For the modality-specific accreditation deep dive, see Intravenous Ketamine Therapy.

The Special Access Program — what it is and why ketamine doesn't need it

Patients researching ketamine sometimes encounter the term "Health Canada Special Access Program (SAP)." This is the legal pathway by which Canadian prescribers can request access to drugs not yet approved in Canada for individual patients with serious or life-threatening conditions when conventional treatments are unavailable or have failed.

Ketamine and Spravato do NOT require SAP. Ketamine is already Health Canada-approved as an anaesthetic; Spravato is Health Canada-approved for TRD. SAP is the pathway specifically for unapproved drugs.

SAP is the access pathway for psilocybin and MDMA. Health Canada amended SAP in January 2022 to include psychedelics for clinical use. Psilocybin SAP authorizations are typically granted for end-of-life distress and treatment-resistant depression with documented prior treatment failures; MDMA-assisted therapy for PTSD has been approved through SAP on a case-specific basis. As of recent reporting, MDMA SAP approvals in Canada have been substantially fewer than psilocybin.

The practical implication: legal access to ketamine is significantly easier than legal access to psilocybin or MDMA in Canada because ketamine does not require SAP. This is a meaningful regulatory advantage for the ketamine pathway.

For the cross-treatment comparison, see Ketamine vs Psilocybin Therapy.

Recreational ketamine versus therapeutic ketamine

Recreational ketamine — possessed and used outside a prescription — is illegal under CDSA Schedule I and carries criminal penalties. The clinical-recreational distinction matters here, both legally and pharmacologically:

For the safety profile deep dive, see Ketamine Therapy Side Effects.

How ATMA CENA operates within the legal framework

ATMA CENA's corporate clinics in Edmonton and Calgary deliver ketamine-assisted therapy under the Alberta CPSA framework. The full picture for any patient:

1. Authorized prescriber. Ketamine prescribing requires an authorized prescriber under provincial regulator standards. ATMA CENA's clinical team includes physicians and nurse practitioners working within their respective scopes.
2. Facility accreditation. ATMA CENA's corporate clinics operate within the CPSA framework; specific accreditation status (NSHF for IV, where applicable) should be confirmed at intake.
3. Informed consent for off-label use. All patients receive written and verbal informed consent that ketamine for psychiatric indications is off-label, including the regulatory framing this article describes.
4. Coordinated psychiatric care. ATMA CENA's coordinated care model supports ongoing coordination with the patient's primary care physician or psychiatrist where applicable.

For city- and province-specific clinic and access information, see the city spokes in this cluster.

Frequently asked questions

Is ketamine therapy legal in Canada? Yes. Ketamine is Schedule I under the CDSA — controlled and prescription-required, but legally available through authorized prescribers. Health Canada has approved racemic ketamine as an anaesthetic; psychiatric use is off-label, which is legal and standard. Spravato is Health Canada-approved for TRD.

Is off-label ketamine illegal? No. Off-label prescribing is legal Canadian medical practice, supported by the CMPA and provincial colleges. Many widely used medications are routinely off-label.

Do I need Health Canada Special Access Program approval? No. SAP is for drugs not approved in Canada. Ketamine is already approved as an anaesthetic; Spravato is approved for TRD. Patients pursuing psilocybin or MDMA-assisted therapy do require SAP — see Ketamine vs Psilocybin Therapy.

What if I'm in Saskatchewan and the clinic doesn't have NHTF accreditation? CPSS January 2021 position is that all parenteral routes (IV, IM, SQ) require CPSS-accredited Non-Hospital Treatment Facility status. Sublingual and oral routes have lighter requirements. Confirm any clinic's accreditation before booking. See Ketamine Therapy in Saskatoon.

What about Quebec's Bill 21 and psychotherapy? Quebec is the only province where psychotherapy is a reserved act under Bill 21 (loi 21, 2009). Only physicians, psychologists, and Ordre des psychologues du Québec permit holders may deliver psychotherapy. The practical implication for KAP in Quebec: the therapy component must be delivered by a permit-holder, physician, or psychologist. See Ketamine Therapy in Montreal.

Is ketamine therapy legal in every Canadian province? Yes — federal CDSA framework applies nationally and Health Canada drug approvals apply across all provinces. Provincial differences are in facility-accreditation requirements and (in Quebec) reserved-act psychotherapy scope.

Can my GP prescribe ketamine? A general practitioner physician is technically authorized to prescribe Schedule I substances, but ketamine for psychiatric indications typically involves specialized clinical infrastructure (IV protocols, monitoring, accredited facility). In practice, ketamine prescribing for psychiatry is concentrated in specialty clinics. For chronic pain, anesthesiology and pain medicine specialist clinics are the typical setting.

Does the Janssen Journey program apply only to Spravato? Yes. Janssen Journey is the controlled-distribution program for Spravato (esketamine). Generic racemic ketamine is not part of the Janssen Journey program; its distribution is governed by the standard CDSA controlled-substance framework.

What are the criminal penalties for unauthorized ketamine possession? Possession of a Schedule I substance without authorization is a criminal offence under the CDSA, with penalties up to imprisonment depending on circumstances. Trafficking and production carry more severe penalties. The clinical pathway through a prescriber is the legal route.

How do I confirm a ketamine clinic is operating legally? Reputable clinics provide on request: the prescriber's regulatory body and registration number, the clinic's facility accreditation (where applicable for the province), and the informed-consent process for off-label use. The ATMA CENA intake call walks through these.

Sources

1. ATMA CENA — coordinated care: https://psychedelic.healthcare/find-care
2. Health Canada — Ketamine: https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/ketamine.html
3. Health Canada DPD — Spravato: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
4. Government of Canada — Controlled Drugs and Substances Act: https://laws-lois.justice.gc.ca/eng/acts/C-38.8/
5. Canadian Medical Protective Association — Off-label use of drugs: https://www.cmpa-acpm.ca/
6. CPSA Alberta — Ketamine Clinical Toolkit: https://cpsa.ca/resources/ketamine-toolkit/
7. CPSO Ontario — Out-of-Hospital Premises Inspection Program: https://www.cpso.on.ca/physicians/your-practice/accreditation-programs/out-of-hospital-premises-inspection-program
8. CPSBC British Columbia — NHMSFAP IV Ketamine for Mood Disorders: https://www.cpsbc.ca/files/pdf/NHMSFAP-AS-Intravenous-Use-of-Ketamine-for-the-Treatment-of-Mood-Disorders.pdf
9. CPSS Saskatchewan — Off-label Ketamine Use Position (January 2021): https://www.cps.sk.ca/iMIS/Documents/For%20Physicians/Advisories%20and%20Positions/2021.01.19%20Ketamine%20off-label%20use%20CPSS%20position%20document.pdf
10. Health Canada — Special Access Program (psychedelic-assisted psychotherapy): https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html

Related articles in this cluster

• Ketamine Therapy in Canada
• What Is Ketamine Therapy?
• Intravenous Ketamine Therapy
• Intranasal Ketamine and Spravato
• Ketamine Therapy Side Effects
• How to Qualify for Ketamine Therapy in Canada
• Ketamine vs Psilocybin Therapy
• Insurance Coverage for Ketamine Therapy
• Find care near you

Last updated: 2026-05-06